Efficacy by patient type

SPIOLTO® RESPIMAT® is indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1

COPD patients qualifying for maintenance treatments can receive benefits from using SPIOLTO® RESPIMAT®. Consistent superiority has been demonstrated for SPIOLTO® RESPIMAT® over SPIRIVA® and placebo, with the greatest improvements in lung function and quality of life (QoL) seen in maintenance‑naïve* patients, including patients with GOLD 2 airflow limitation.2,3

A symptomatic patient naive to COPD maintenance therapy:

An example of a patient of this type is someone who is symptomatic with no exacerbations in the last 12 months and can be classified as a GOLD B patient.4

Based on the GOLD 2017 report, GOLD B patients with severe breathlessness could be started on LAMA/LABA therapy.4

SPIOLTO® RESPIMAT® offers consistent benefits beyond SPIRIVA® from the start of maintenance therapy, across key COPD endpoints:

  • A reduction in breathlessness over SPIRIVA®5
  • Significant improvement in quality of life over SPIRIVA® and placebo5
  • Improved lung function improvement beyond SPIRIVA®3

The safety profile of SPIOLTO® RESPIMAT® is comparable to that of its monocomponents.1,7

A symptomatic patient already treated with SPIRIVA®:

An example of a patient of this type is someone who is already treated with SPIRIVA® but is symptomatic with 2 moderate exacerbations in the last few months and can be classified as a GOLD D patient.

Based on the GOLD 2017 report, GOLD D patients currently on a LAMA who experience further exacerbations could be changed to a LAMA/LABA.4

SPIOLTO® RESPIMAT® offers consistent benefits beyond SPIRIVA across key COPD endpoints:

  • A reduction in breathlessness over SPIRIVA®2,6
  • Significant improvement in quality of life2,7
  • Significant improvement in lung function over SPIRIVA® and reduction of hyperinflation7,8

The safety profile of SPIOLTO® RESPIMAT® is comparable to that of its monocomponents.1,7

A symptomatic patient on LABA/ICS (infrequent exacerbator):

An example of a patient of this type is someone who is symptomatic with 1 moderate exacerbation in the last few months despite treatment with a LABA/ICS, i.e. who can be classified as a GOLD B patient.4

Based on the GOLD 2017 report, GOLD B patients with confirmed COPD should not be treated with LABA/ICS. Patients with persistent symptoms could be changed to LAMA/LABA.4

SPIOLTO® RESPIMAT® offers significant improvements in lung function over LABA/ICS.9

Potential risks associated with long term ICS use can be avoided.10

Patients with co-morbidities

For more information on prescribing SPIOLTO® RESPIMAT® in patients with comorbidities (e.g. cardiovascular risk, hepatic or renal impairment) please see section 4.4 of the SmPC.

Interaction with other medications

For more information on prescribing SPIOLTO® RESPIMAT® in patients taking other medications and the possible interactions please see Drug Interactions in section 4.5 of the SmPC.

*without previous maintenance LAMA or LABA therapy

References

  1. SPIOLTO® RESPIMAT® Summary of Product Characteristics February 2017.
  2. Singh D, et al. Respir Med. 2015;109:1312-1319.
  3. Ferguson GT, et al. Adv Ther 2015; 32: 523-536; Ferguson GT, et al. Adv Ther 2015; 32: 523-536 (supplementary material).
  4. GOLD COPD strategy report 2017. Available at: 
    http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd 
    [Accessed June 2017].
  5. Singh D et al. Resp Res 2016 ;17(73) :1-3 and supplementary information
  6. Witek T, et al. Eur Respir J. 2003;21 :267-272.
  7. Buhl R, et al. Eur Respir J. 2015;45:969-979.
  8. Beeh KM, et al. Pulm Pharmacol Ther. 2015;32:53-59.
  9. Beeh KM, et al. Int J Chron Obstruct Pulmon Dis. 2016;11:193-205.
  10. Price D, et al. Prim Care Respir J. 2013; 22(1):92-100.